Alzheimer's Disease Global Clinical Trials Review, H2, 2016

Date: August 17, 2016
Pages: 912
Price:
US$ 2,500.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A1D2800DDACEN
Leaflet:

Download PDF Leaflet

Alzheimer's Disease Global Clinical Trials Review, H2, 2016

SUMMARY

GlobalData's clinical trial report, “Alzheimer's Disease Global Clinical Trials Review, H2, 2016' provides an overview of Alzheimer's Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Alzheimer's Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

REASONS TO BUY
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Report Guidance
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Alzheimer's Disease Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Alzheimer's Disease
Aug 09, 2016: U.S. FDA Confirms Sufficient Data to Advance Investigational Bace Inhibitor E2609 for Treatment of Early Alzheimer’s Disease to Phase III
Aug 02, 2016: Accera Appoints C. Evan Ballantyne as Chief Financial Officer
Aug 01, 2016: The results of phase I clinical trial of the Araclon Biotech Alzheimers vaccine support its continuation
Jul 29, 2016: Anavex Confirms Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients Presented at AAIC 2016
Jul 27, 2016: TauRx Reports First Phase 3 Results for LMTX
Jul 27, 2016: Oryzon Initiates Multiple Ascending Dose Cohorts in ORY-2001 Phase 1 Clinical Trial
Jul 27, 2016: vTv Therapeutics Announces Presentation of Phase 2b Azeliragon Results at the 2016 Alzheimer’s Association International Conference
Jul 27, 2016: Stemedica Begins First Clinical Trials In The U.S. Using Adult Allogeneic Stem Cells To Treat Alzheimer Disease
Jul 27, 2016: Actinogen Medical Announces Landmark Research on Excess Cortisol and Alzheimer's Disease
Jul 27, 2016: Anavex Presents 31-Week Efficacy Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer’s Patients at AAIC 2016
Jul 27, 2016: Prana Alzheimers disease data features at world leading conference
Jul 25, 2016: Alzheon Presents Positive Results of ALZ-801 Clinical Studies that Lead to Advancement to Pivotal Phase 3 Study in Alzheimer Patients with APOE4/4 Homozygous Genotype
Jul 24, 2016: Anavex Presents 31-Week Safety Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients at AAIC 2016
Jul 20, 2016: Corium to Present Clinical Data from a Phase 1 Pharmacokinetic Study of Once-Weekly Corplex Donepezil Transdermal System
Jul 14, 2016: vTv Therapeutics Announces Phase 2b Azeliragon Data Selected for Oral Presentation at the 2016 Alzheimer's Association International Conference
Jul 13, 2016: IntelGenx to Initiate Phase 1 Trial of Montelukast
Jul 12, 2016: Anavex to Present at the Alzheimer’s Association International Conference (AAIC) 2016
Jul 07, 2016: AC Immune to receive milestone payment for Anti-Tau Antibody moving into Phase 1 trial for Alzheimer’s disease
Jun 28, 2016: Intra-Cellular Therapies Announces Initiation of ITI-007-201 Phase 3 Clinical Trial for the Treatment of Agitation in Patients with Dementia, Including Alzheimer’s Disease
Jun 22, 2016: AXON Pioneering Tau Vaccine against Alzheimers Started Phase II
Jun 21, 2016: Bryostatin, a PKC epsilon Activator, Generates New Synapses Through Accumulation of the Synaptic Anchoring Protein PSD-95 at Neuronal Membranes
Jun 14, 2016: New Alzheimers Study Aimed at Preventing or Delaying Symptoms
Jun 06, 2016: IL-33 ameliorates Alzheimers-like pathology and cognitive decline
Clinical Trial Profile Snapshots
Appendix
Abbreviations
Definitions
Research Methodology
Secondary Research
About GlobalData
Contact Us
Disclaimer
Source

LIST OF TABLES

Alzheimer's Disease Therapeutics, Global, Clinical Trials by Region, 2016
Alzheimer's Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016
Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016
Alzheimer's Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016
Alzheimer's Disease Therapeutics Clinical Trials, Europe, Top Five Countries, 2016
Alzheimer's Disease Therapeutics Clinical Trials, North America, Top Countries, 2016
Alzheimer's Disease Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016
Alzheimer's Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016
Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, G7 Countries (%), 2016
Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2016
Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016
Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, E7 Countries (%), 2016
Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2016
Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016
Alzheimer's Disease Therapeutics, Global, Clinical Trials by Phase, 2016
Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Phase 2016
Alzheimer's Disease Therapeutics, Global, Clinical Trials by Trial Status, 2016
Alzheimer's Disease Therapeutics Clinical Trials, Global, by End Point Status, 2016
Alzheimer's Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
Alzheimer's Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016
Alzheimer's Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2016
Alzheimer's Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016
Alzheimer's Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016

LIST OF FIGURES

Alzheimer's Disease Therapeutics, Global, Clinical Trials by Region (%), 2016
Alzheimer's Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016
Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016
Alzheimer's Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016
Alzheimer's Disease Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016
Alzheimer's Disease Therapeutics Clinical Trials, North America, Top Countries (%), 2016
Alzheimer's Disease Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016
Alzheimer's Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016
Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, G7 Countries (%), 2016
Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2016
Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016
Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, E7 Countries (%), 2016
Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2016
Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016
Alzheimer's Disease Therapeutics, Global, Clinical Trials by Phase (%), 2016
Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Phase, 2016
Alzheimer's Disease Therapeutics, Global, Clinical Trials by Trial Status, 2016
Alzheimer's Disease Therapeutics Clinical Trials, Global, by End Point Status, 2016
Alzheimer's Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
Alzheimer's Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016
Alzheimer's Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2016
Alzheimer's Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016
Alzheimer's Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016
GlobalData Methodology

COMPANIES MENTIONED

Pfizer Inc.
Johnson & Johnson
Eisai Co., Ltd.
F. Hoffmann-La Roche Ltd.
Eli Lilly and Company
Novartis AG
AstraZeneca Plc
GlaxoSmithKline Plc
AbbVie Inc
Merck & Co., Inc.
Skip to top


Ask Your Question

Alzheimer's Disease Global Clinical Trials Review, H2, 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: